José P S Henriques

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6687688/publications.pdf

Version: 2024-02-01

252 papers

13,760 citations

20759 60 h-index 24179

264 all docs 264 docs citations

times ranked

264

9907 citing authors

g-index

#	Article	IF	CITATIONS
1	A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary Intervention. Circulation, 2012, 126, 1717-1727.	1.6	680
2	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon PumpÂin Cardiogenic Shock After AcuteÂMyocardial Infarction. Journal of the American College of Cardiology, 2017, 69, 278-287.	1.2	612
3	A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines?. European Heart Journal, 2008, 30, 459-468.	1.0	452
4	Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Medicine, 2016, 42, 1922-1934.	3.9	405
5	Coronary Angiography after Cardiac Arrest without ST-Segment Elevation. New England Journal of Medicine, 2019, 380, 1397-1407.	13.9	373
6	Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. New England Journal of Medicine, 2017, 376, 2319-2328.	13.9	363
7	Impella Support for Acute Myocardial Infarction Complicated by Cardiogenic Shock. Circulation, 2019, 139, 1249-1258.	1.6	353
8	Angiographic Assessment of Reperfusion in Acute Myocardial Infarction by Myocardial Blush Grade. Circulation, 2003, 107, 2115-2119.	1.6	350
9	Physiological Basis and Long-Term Clinical Outcome of Discordance Between Fractional Flow Reserve and Coronary Flow Velocity Reserve in Coronary Stenoses of Intermediate Severity. Circulation: Cardiovascular Interventions, 2014, 7, 301-311.	1.4	322
10	Percutaneous Intervention for ConcurrentÂChronic Total Occlusions inÂPatients WithÂSTEMI. Journal of the American College of Cardiology, 2016, 68, 1622-1632.	1.2	300
11	A Prospective Feasibility Trial Investigating the Use of the Impella 2.5 System in Patients Undergoing High-Risk Percutaneous Coronary Intervention (The PROTECT I Trial). JACC: Cardiovascular Interventions, 2009, 2, 91-96.	1.1	295
12	Plaque Instability Frequently Occurs Days or Weeks Before Occlusive Coronary Thrombosis. Circulation, 2005, 111, 1160-1165.	1.6	287
13	Percutaneous short-term active mechanical support devices in cardiogenic shock: a systematic review and collaborative meta-analysis of randomized trials. European Heart Journal, 2017, 38, 3523-3531.	1.0	280
14	Percutaneous Left-Ventricular Support With the Impella-2.5â€"Assist Device in Acute Cardiogenic Shock. Circulation: Heart Failure, 2013, 6, 23-30.	1.6	278
15	Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation, 2019, 140, 420-433.	1.6	263
16	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2011, 4, 952-961.	1.1	260
17	Supported High-Risk Percutaneous Coronary Intervention With the Impella 2.5 Device. Journal of the American College of Cardiology, 2009, 54, 2430-2434.	1.2	210
18	Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2009, 2, 1128-1134.	1.1	208

#	Article	IF	CITATIONS
19	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. European Heart Journal, 2012, 33, 768-775.	1.0	206
20	Safety and Feasibility of Elective High-Risk Percutaneous Coronary Intervention Procedures With Left Ventricular Support of the Impella Recover LP 2.5. American Journal of Cardiology, 2006, 97, 990-992.	0.7	205
21	Effects of left ventricular unloading by Impella recover LP2.5 on coronary hemodynamics. Catheterization and Cardiovascular Interventions, 2007, 70, 532-537.	0.7	161
22	Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user group. International Journal of Cardiology, 2015, 201, 684-691.	0.8	160
23	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	1.1	159
24	A single dose of erythropoietin in ST-elevation myocardial infarction. European Heart Journal, 2010, 31, 2593-2600.	1.0	144
25	Presence of Older Thrombus Is an Independent Predictor of Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Thrombus Aspiration During Primary Percutaneous Coronary Intervention. Circulation, 2008, 118, 1810-1816.	1.6	135
26	Left ventricular unloading during veno-arterial ECMO: a review of percutaneous and surgical unloading interventions. Perfusion (United Kingdom), 2019, 34, 98-105.	0.5	130
27	Impact of Multivessel Coronary Disease on Long-Term Mortality in Patients With ST-Elevation Myocardial Infarction Is Due to the Presence of a Chronic Total Occlusion. American Journal of Cardiology, 2006, 98, 1165-1169.	0.7	126
28	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. International Journal of Cardiology, 2015, 187, 90-96.	0.8	126
29	Prognostic value of admission glucose in non-diabetic patients with myocardial infarction. American Heart Journal, 2004, 148, 399-404.	1.2	124
30	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). European Heart Journal, 2020, 41, 3715-3728.	1.0	121
31	Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention, 2015, 10, 1160-1168.	1.4	118
32	Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). American Journal of Cardiology, 2014, 113, 222-228.	0.7	116
33	Left Ventricular Unloading During Veno-Arterial ECMO: A Simulation Study. ASAIO Journal, 2019, 65, 11-20.	0.9	112
34	Global Chronic Total Occlusion CrossingÂAlgorithm. Journal of the American College of Cardiology, 2021, 78, 840-853.	1,2	111
35	Chronic Total Occlusions in Sweden – A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). PLoS ONE, 2014, 9, e103850.	1.1	108
36	Genousâ,,¢ endothelial progenitor cell capturing stent vs. the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. European Heart Journal, 2010, 31, 1055-1064.	1.0	106

#	Article	IF	CITATIONS
37	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intensive Care Medicine, 2018, 44, 847-856.	3.9	106
38	Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock. American Journal of Cardiology, 2010, 105, 955-959.	0.7	105
39	Impact of hyperaemic microvascular resistance on fractional flow reserve measurements in patients with stable coronary artery disease: insights from combined stenosis and microvascular resistance assessment. Heart, 2014, 100, 951-959.	1.2	102
40	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	1.1	101
41	Percutaneous Mechanical Circulatory Support Versus Intra-Aortic Balloon Pump for Treating Cardiogenic Shock. Journal of the American College of Cardiology, 2017, 69, 358-360.	1.2	98
42	Risk factors for primary ventricular fibrillation during acute myocardial infarction: a systematic review and meta-analysis. European Heart Journal, 2006, 27, 2499-2510.	1.0	97
43	The ICM research agenda on extracorporeal life support. Intensive Care Medicine, 2017, 43, 1306-1318.	3.9	94
44	The Prognostic Value of Bleeding Academic Research Consortium (BARC)-Defined BleedingÂComplications in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 1866-1875.	1.2	93
45	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. Journal of the American College of Cardiology, 2020, 75, 2664-2678.	1.2	93
46	Effects of mechanical left ventricular unloading by impella on left ventricular dynamics in highâ \in risk and primary percutaneous coronary intervention patients. Catheterization and Cardiovascular Interventions, 2010, 75, 187-194.	0.7	91
47	Multiple Biomarkers at Admission Significantly Improve the Prediction of Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 29-36.	1.2	91
48	The impact of multivessel disease with and without a coâ€existing chronic total occlusion on short― and longâ€ŧerm mortality in STâ€elevation myocardial infarction patients with and without cardiogenic shock. European Journal of Heart Failure, 2013, 15, 425-432.	2.9	90
49	Left Ventricular Unloading in Acute ST-Segment Elevation Myocardial Infarction Patients Is Safe and Feasible and Provides Acute and Sustained Left Ventricular Recovery. Journal of the American College of Cardiology, 2008, 51, 1044-1046.	1.2	89
50	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the TreatmentÂof Any In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 275-283.	1.1	88
51	Randomized Multicenter Trial InvestigatingÂAngiographic Outcomes ofÂHybrid Sirolimus-Eluting Stents WithÂBiodegradable Polymer Compared WithÂEverolimus-Eluting Stents With DurableÂPolymer in Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2017, 10, 133-143.	1.1	83
52	Impact of Coronary Microvascular Function on Long-term Cardiac Mortality in Patients With Acute ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 207-215.	1.4	77
53	Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock International Journal of Cardiology, 2016, 202, 894-896.	0.8	76
54	Mechanical circulatory support in cardiogenic shock from acute myocardial infarction: Impella CP/5.0 versus ECMO. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 164-172.	0.4	72

#	Article	IF	CITATIONS
55	Interferon-Î ² Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice. Circulation Research, 2008, 102, 1286-1294.	2.0	66
56	Impaired Coronary Autoregulation Is Associated With Long-term Fatal Events in Patients With Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2013, 6, 329-335.	1.4	65
57	Prognostic Impact of ChronicÂTotalÂOcclusions. JACC: Cardiovascular Interventions, 2016, 9, 1535-1544.	1.1	65
58	Coronary Angiography After Cardiac Arrest Without ST Segment Elevation. JAMA Cardiology, 2020, 5, 1358.	3.0	65
59	Improved microcirculation in patients with an acute ST-elevation myocardial infarction treated with the Impella LP2.5 percutaneous left ventricular assist device. Clinical Research in Cardiology, 2009, 98, 311-318.	1.5	63
60	Percutaneous cardiac support devices for cardiogenic shock: current indications and recommendations. Heart, 2012, 98, 1246-1254.	1.2	62
61	Head-to-head comparison of basal stenosis resistance index, instantaneous wave-free ratio, and fractional flow reserve: diagnostic accuracy for stenosis-specific myocardial ischaemia. EuroIntervention, 2015, 11, 914-925.	1.4	62
62	Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart, 2010, 96, 843-847.	1.2	60
63	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Trials, 2010, 11, 89.	0.7	58
64	Clinical and Procedural Characteristics Associated With Higher Radiation Exposure During Percutaneous Coronary Interventions and Coronary Angiography. Circulation: Cardiovascular Interventions, 2013, 6, 501-506.	1.4	58
65	Right ventricular dysfunction is an independent predictor for mortality in STâ€elevation myocardial infarction patients presenting with cardiogenic shock on admission. European Journal of Heart Failure, 2010, 12, 276-282.	2.9	57
66	Anxiety levels of patients undergoing coronary procedures in the catheterization laboratory. International Journal of Cardiology, 2017, 228, 926-930.	0.8	55
67	Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. Heart, 2018, 104, 1432-1438.	1.2	55
68	Real-life use of left ventricular circulatory support with Impella in cardiogenic shock after acute myocardial infarction: 12 years AMC experience. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 338-349.	0.4	55
69	Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. Heart, 2010, 96, 1968-1972.	1.2	52
70	CTCA for detection of significant coronary artery disease in routine TAVI work-up. Netherlands Heart Journal, 2018, 26, 591-599.	0.3	50
71	Histopathological Features of Aspirated Thrombi after Primary Percutaneous Coronary Intervention in Patients with ST-Elevation Myocardial Infarction. PLoS ONE, 2009, 4, e5817.	1.1	49
72	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. Journal of Thrombosis and Thrombolysis, 2014, 37, 155-164.	1.0	49

#	Article	IF	CITATIONS
73	A Systematic Review and Meta-Analysis on Primary Percutaneous Coronary Intervention of an Unprotected Left Main Coronary Artery Culprit Lesion in the Setting of Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2013, 6, 317-324.	1.1	48
74	Efficacy of the RADPAD Protection Drape in Reducing Operators' Radiation Exposure in the Catheterization Laboratory. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	48
75	Impact of target vessel on longâ€ŧerm survival after percutaneous coronary intervention for chronic total occlusions. Catheterization and Cardiovascular Interventions, 2013, 82, 76-82.	0.7	46
76	Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis. European Heart Journal, 2012, 33, 1076-1084.	1.0	44
77	Culprit Vessel–Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	44
78	In patients with ST-segment elevation myocardial infarction with cardiogenic shock treated with percutaneous coronary intervention, admission glucose level is a strong independent predictor for 1-year mortality in patients without a prior diagnosis of diabetes. American Heart Journal, 2007, 154, 1184-1190.	1.2	43
79	Radiation Exposure During Percutaneous Coronary Interventions and Coronary Angiograms Performed by the Radial Compared With the Femoral Route. JACC: Cardiovascular Interventions, 2012, 5, 752-757.	1.1	41
80	Amsterdam Investigator–initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale	1.2	41
81	and study design. American Heart Journal, 2014, 167, 133-140. Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. Journal of Cardiovascular Magnetic Resonance, 2017, 19, 53.	1.6	41
82	Incidence, Predictors, and Impact of Vascular Complications After Transfemoral Transcatheter Aortic Valve Implantation With the SAPIEN 3 Prosthesis. American Journal of Cardiology, 2018, 121, 1231-1238.	0.7	41
83	Comparison of Long-Term Mortality After Percutaneous Coronary Intervention in Patients Treated for Acute ST-Elevation Myocardial Infarction Versus Those With Unstable and Stable Angina Pectoris. American Journal of Cardiology, 2009, 104, 333-337.	0.7	40
84	Prognostic Value of Admission Hemoglobin Levels in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. American Journal of Cardiology, 2007, 99, 1201-1202.	0.7	38
85	Twoâ€year followâ€up of the genousâ,,¢ endothelial progenitor cell capturing stent versus the taxus liberté stent in patients with <i>De Novo</i> coronary artery lesions with a highâ€risk of restenosis. Catheterization and Cardiovascular Interventions, 2011, 78, 189-195.	0.7	38
86	Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention, 2018, 13, 1565-1573.	1.4	35
87	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 622-630.	1.1	34
88	Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study. American Heart Journal, 2014, 167, 472-479.e5.	1.2	34
89	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	6.1	34
90	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	6.1	33

#	Article	IF	Citations
91	Appropriate use of bioresorbable vascular scaffolds in percutaneous coronary interventions: a recommendation from experienced users. Netherlands Heart Journal, 2015, 23, 161-165.	0.3	30
92	Impact of Collateral Circulation on Survival in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With a Concomitant Chronic Total Occlusion. JACC: Cardiovascular Interventions, 2017, 10, 906-914.	1.1	30
93	Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 1009-1015.	0.4	30
94	Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. American Journal of Cardiology, 2017, 120, 2035-2040.	0.7	29
95	The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective. Journal of Medical Economics, 2013, 16, 381-390.	1.0	28
96	Timing of Mortality After Severe Bleeding and Recurrent Myocardial Infarction in Patients With ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 391-398.	1.4	28
97	Coronary angiography after cardiac arrest: Rationale and design of the COACT trial. American Heart Journal, 2016, 180, 39-45.	1.2	28
98	Lactate is a Prognostic Factor in Patients Admitted With Suspected ST-Elevation Myocardial Infarction. Shock, 2019, 51, 321-327.	1.0	28
99	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. European Heart Journal, 2021, 42, 1038-1046.	1.0	28
100	Six-month and one-year clinical outcomes after placement of a dedicated coronary bifurcation stent: a patient-level pooled analysis of eight registry studies. EuroIntervention, 2013, 9, 195-203.	1.4	27
101	Complete two-year follow-up with formal non-inferiority testing on primary outcomes of the AIDA trial comparing the Absorb bioresorbable scaffold with the XIENCE drug-eluting metallic stent in routine PCI. EuroIntervention, 2018, 14, e426-e433.	1.4	26
102	Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention, 2014, 10, 90-96.	1.4	26
103	Long-term safety and sustained left ventricular recovery: long-term results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. EuroIntervention, 2011, 6, 860-865.	1.4	26
104	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	0.7	25
105	Prognostic implications of microcirculatory perfusion versus macrocirculatory perfusion in cardiogenic shock: a CULPRIT-SHOCK substudy. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 108-119.	0.4	25
106	Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. Journal of Invasive Cardiology, 2012, 24, 484-8.	0.4	25
107	Percutaneous mechanical cardiac assist in myocardial infarction. Where are we now, where are we going?. Acute Cardiac Care, 2007, 9, 222-230.	0.2	24
108	Role of fractional and coronary flow reserve in clinical decision making in intermediate coronary lesions. Interventional Cardiology, 2009, 1, 237-255.	0.0	24

#	Article	IF	CITATIONS
109	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?. Netherlands Heart Journal, 2010, 18, 451-453.	0.3	24
110	Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission Acute Cardiac Care, 2010, 12, 51-57.	0.2	24
111	Longâ€term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 Years). Catheterization and Cardiovascular Interventions, 2013, 82, 85-92.	0.7	24
112	Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III): a randomised comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention, 2013, 9, 841-853.	1.4	24
113	Increased hyperaemic coronary microvascular resistance adds to the presence of myocardial ischaemia. EuroIntervention, 2014, 9, 1423-1431.	1.4	23
114	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute STâ€segment elevation myocardial infarction: Results of the ⟨scp⟩HORIZONSâ€AMI⟨/scp⟩ trial. Catheterization and Cardiovascular Interventions, 2015, 85, 335-342.	0.7	22
115	Guideline-defined futility or patient-reported outcomes to assess treatment success after TAVI: what to use? Results from a prospective cohort study with long-term follow-up. Open Heart, 2018, 5, e000879.	0.9	21
116	Vasopressors and Inotropes in Acute Myocardial Infarction Related Cardiogenic Shock: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2051.	1.0	21
117	Time to Return of Spontaneous Circulation and Survival: When to Transport in out-of-Hospital Cardiac Arrest?. Prehospital Emergency Care, 2021, 25, 171-181.	1.0	21
118	CT determined psoas muscle area predicts mortality in women undergoing transcatheter aortic valve implantation. Catheterization and Cardiovascular Interventions, 2019, 93, E248-E254.	0.7	20
119	Comparison of Outcomes of Transfemoral Aortic Valve Implantation in Patients <90 With Those >90 Years of Age. American Journal of Cardiology, 2018, 121, 1581-1586.	0.7	18
120	Adjunctive thrombus aspiration versus conventional percutaneous coronary intervention in STâ€elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 81, 922-929.	0.7	16
121	Predictors and prognostic consequence of gastrointestinal bleeding in patients with ST-segment elevation myocardial infarction. International Journal of Cardiology, 2015, 184, 128-134.	0.8	15
122	The IMPACT Study (Influence of Sensor-Equipped Microcatheters on Coronary Hemodynamics and the) Tj ETQq0 C Interventions, 2016, 9, .	0 rgBT /0 1.4	Overlock 10 15
123	Basal stenosis resistance index derived from simultaneous pressure and flow velocity measurements. EuroIntervention, 2016, 12, e199-e207.	1.4	15
124	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2012, 34, 165-179.	1.0	14
125	Clinical outcomes after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions treated with a dedicated coronary bifurcation stent. Heart, 2014, 100, 479-486.	1.2	14
126	Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock. PLoS ONE, 2020, 15, e0235762.	1.1	14

#	Article	IF	CITATIONS
127	Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial. EuroIntervention, 2018, 14, e434-e442.	1.4	14
128	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. Journal of Clinical Medicine, 2022, $11,1361.$	1.0	14
129	First report of the use of longâ€tapered sirolimusâ€eluting coronary stent for the treatment of chronic total occlusions with the hybrid algorithm. Catheterization and Cardiovascular Interventions, 2018, 92, E299-E307.	0.7	13
130	Procedural Outcome and Midterm Survival of Lower Risk Transfemoral Transcatheter Aortic Valve Implantation Patients Treated With the SAPIEN XT or SAPIEN 3 Device. American Journal of Cardiology, 2018, 121, 856-861.	0.7	13
131	Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Longâ€Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverterâ€Defibrillator (the eCTOpyâ€inâ€ICD Study). Journal of the American Heart Association, 2018, 7,	1.6	13
132	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. European Radiology, 2020, 30, 600-608.	2.3	13
133	Treatment of coronary bifurcation lesions with the Absorb bioresorbable vascular scaffold in combination with the Tryton dedicated coronary bifurcation stent: evaluation using two- and three-dimensional optical coherence tomography. EuroIntervention, 2015, 11, 877-884.	1.4	13
134	Long Term Effects of Epoetin Alfa in Patients with ST- Elevation Myocardial Infarction. Cardiovascular Drugs and Therapy, 2013, 27, 433-439.	1.3	12
135	Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: AÂweighted meta-analysis of seven randomised controlled trials including 5577 patients. Netherlands Heart Journal, 2017, 25, 429-438.	0.3	12
136	Aortic valve calcification volumes and chronic brain infarctions in patients undergoing transcatheter aortic valve implantation. International Journal of Cardiovascular Imaging, 2019, 35, 2123-2133.	0.7	12
137	Gender differences in quality of life in coronary artery disease patients with comorbidities undergoing coronary revascularization. PLoS ONE, 2020, 15, e0234543.	1.1	12
138	New percutaneous mechanical left ventricular support for acute MI: the AMC MACH program. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 62-63.	3. 3	11
139	Current status of the Xience V ^{$\hat{A}^{@}$} everolimus-eluting coronary stent system. Expert Review of Cardiovascular Therapy, 2010, 8, 1363-1374.	0.6	11
140	Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI. Thrombosis and Haemostasis, 2013, 109, 961-970.	1.8	11
141	Older coronary thrombus is an independent predictor of 1â€year mortality in acute myocardial infarction. European Journal of Clinical Investigation, 2016, 46, 501-510.	1.7	11
142	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. Open Heart, 2018, 5, e000810.	0.9	11
143	3-Year Clinical Outcomes of the PRISON-IV Trial. JACC: Cardiovascular Interventions, 2019, 12, 1747-1749.	1.1	11
144	The dynamics in health-related quality of life of patients with stable coronary artery disease were revealed: a network analysis. Journal of Clinical Epidemiology, 2019, 107, 116-123.	2.4	11

#	Article	IF	Citations
145	External validation of existing prediction models of 30-day mortality after Transcatheter Aortic Valve Implantation (TAVI) in the Netherlands Heart Registration. International Journal of Cardiology, 2020, 317, 25-32.	0.8	11
146	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent in routine PCI: three-year clinical outcomes from the AIDA trial. EuroIntervention, 2019, 15, 603-606.	1.4	11
147	Two-year clinical outcomes of Absorb bioresorbable vascular scaffold implantation in complex coronary artery disease patients stratified by SYNTAX score and ABSORB II study enrolment criteria. EuroIntervention, 2016, 12, e557-e565.	1.4	11
148	Creatinine clearance is independently associated with one year mortality in a primary PCI cohort with cardiogenic shock. Acute Cardiac Care, 2009, 11, 107-112.	0.2	10
149	A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study. Trials, 2012, 13, 240.	0.7	10
150	Predicting hospitalisation duration after transcatheter aortic valve implantation. Open Heart, 2017, 4, e000549.	0.9	10
151	Electrocardiographic changes after successful recanalization of a chronic total coronary occlusion. A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 2018, 19, 221-228.	0.3	10
152	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. Structural Heart, 2018, 2, 53-57.	0.2	10
153	Quantification of Myocardial Mass Subtended by a Coronary Stenosis Using Intracoronary Physiology. Circulation: Cardiovascular Interventions, 2019, 12, e007322.	1.4	10
154	Influence of response shift and disposition on patient-reported outcomes may lead to suboptimal medical decisions: a medical ethics perspective. BMC Medical Ethics, 2019, 20, 61.	1.0	10
155	Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: aÂsystematic review and meta-analysis of randomised trials. Netherlands Heart Journal, 2021, 29, 30-41.	0.3	10
156	Impella CP Implantation during Cardiopulmonary Resuscitation for Cardiac Arrest: A Multicenter Experience. Journal of Clinical Medicine, 2021, 10, 339.	1.0	10
157	Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis. ESC Heart Failure, 2021, 8, 953-961.	1.4	10
158	DEtection of ProxImal Coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration). European Radiology, 2022, 32, 143-151.	2.3	10
159	Identification and treatment of the vulnerable coronary plaque. Reviews in Cardiovascular Medicine, 2022, 23, 1.	0.5	10
160	External validation of the GRACE risk score and the risk–treatment paradox in patients with acute coronary syndrome. Open Heart, 2022, 9, e001984.	0.9	10
161	Long-term clinical outcomes of everolimus-eluting bioresorbable scaffolds versus everolimus-eluting stents: final five-year results of the AIDA randomised clinical trial. EuroIntervention, 2022, 17, 1340-1347.	1.4	10
162	Sensor-Augmented Insulin Pump Therapy to Treat Hyperglycemia at the Coronary Care Unit: A Randomized Clinical Pilot Trial. Diabetes Technology and Therapeutics, 2010, 12, 537-542.	2.4	9

#	Article	IF	Citations
163	Short―and Longâ€Term Prognostic Value of the TIMI Risk Score after Primary Percutaneous Coronary Intervention for STâ€segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 8-13.	0.5	9
164	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention — From the PROTECT II randomized trial. International Journal of Cardiology, 2015, 189, 272-278.	0.8	9
165	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. Journal of Thrombosis and Thrombolysis, 2016, 41, 441-451.	1.0	9
166	Impact of ultraâ€thin struts on restenosis after chronic total occlusion recanalization: Insights from the randomized PRISON IV trial. Journal of Interventional Cardiology, 2018, 31, 580-587.	0.5	9
167	Clinical Implications of Distal Vessel Stenosis After Successful Coronary Chronic TotalÂOcclusion Recanalization. JACC: Cardiovascular Interventions, 2018, 11, 2343-2345.	1.1	9
168	The effect of immediate coronary angiography after cardiac arrest without ST-segment elevation on left ventricular function. A sub-study of the COACT randomised trial. Resuscitation, 2021, 164, 93-100.	1.3	9
169	Three-year clinical outcome in the Primary Stenting of Totally Occluded Native Coronary Arteries III (PRISON III) trial: a randomised comparison between sirolimus-eluting stent implantation and zotarolimus-eluting stent implantation for the treatment of total coronary occlusions. EuroIntervention, 2015, 10, 1272-1275.	1.4	9
170	First report on longâ€term clinical results after treatment of coronary bifurcation lesions with the Tryton dedicated bifurcation stent. Catheterization and Cardiovascular Interventions, 2014, 84, 759-765.	0.7	8
171	Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. Netherlands Heart Journal, 2015, 23, 477-482.	0.3	8
172	A SMILE and a Frown. Journal of the American College of Cardiology, 2016, 67, 273-274.	1.2	8
173	Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock. American Journal of Cardiology, 2018, 122, 1661-1669.	0.7	8
174	Online Quantitative Aortographic Assessment of Aortic Regurgitation AfterÂTAVR. JACC: Cardiovascular Interventions, 2021, 14, 531-538.	1.1	8
175	Response shift after coronary revascularization. Quality of Life Research, 2022, 31, 437-450.	1.5	8
176	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. EuroIntervention, 2016, 12, 423-430.	1.4	8
177	Deep learning-based whole-heart segmentation in 4D contrast-enhanced cardiac CT. Computers in Biology and Medicine, 2022, 142, 105191.	3.9	8
178	Evaluation of a Fully Automatic Deep Learning-Based Method for the Measurement of Psoas Muscle Area. Frontiers in Nutrition, 2022, 9, .	1.6	8
179	Plasma glucose and not hemoglobin or renal function predicts mortality in patients with STEMI complicated with cardiogenic shock. Journal of Cardiovascular Medicine, 2010, 11, 827-831.	0.6	7
180	Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Does Coronary Pressure Never Lie?. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 294.	0.4	7

#	Article	IF	CITATIONS
181	Predictors of medium-term mortality in patients hospitalised with coronary artery disease in a resource-limited South-East Asian setting. Open Heart, 2018, 5, e000801.	0.9	7
182	Premedication to reduce anxiety in patients undergoing coronary angiography and percutaneous coronary intervention. Open Heart, 2018, 5, e000833.	0.9	7
183	Tele-ECG consulting and outcomes on primary care patients in a low-to-middle income population: the first experience from Makassar telemedicine program, Indonesia. BMC Family Practice, 2020, 21, 247.	2.9	7
184	Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries. Cardiovascular Drugs and Therapy, 2021, 35, 1171-1182.	1.3	7
185	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2013, 35, 200-208.	1.0	6
186	Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication. European Heart Journal, 2016, 37, 1104-1112.	1.0	6
187	Scaffold thrombosis following implantation of the ABSORB BVS in routine clinical practice: Insight into possible mechanisms from optical coherence tomography. Catheterization and Cardiovascular Interventions, 2018, 92, E106-E114.	0.7	6
188	The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial. Journal of Electrocardiology, 2018, 51, 906-912.	0.4	6
189	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. International Journal of Cardiovascular Imaging, 2019, 35, 1189-1198.	0.7	6
190	Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion(from the EXPLORE Trial). American Journal of Cardiology, 2019, 123, 1035-1043.	0.7	6
191	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine―in Daily Clinical Practice. Journal of Clinical Medicine, 2020, 9, 3173.	1.0	6
192	Collagenase to facilitate guidewire crossing in chronic total occlusion PCl—The Total Occlusion Study in Coronary Arteriesâ€5 (TOSCAâ€5) trial. Catheterization and Cardiovascular Interventions, 2022, 99, 1065-1073.	0.7	6
193	Monocytic microRNA profile associated with coronary collateral artery function in chronic total occlusion patients. Scientific Reports, 2017, 7, 1532.	1.6	5
194	Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients. Journal of the American College of Cardiology, 2017, 69, 2347-2348.	1.2	5
195	Revascularization Strategies in Cardiogenic Shock Patients With MVD. Journal of the American College of Cardiology, 2018, 71, 857-859.	1.2	5
196	Sex differences in patients with out-of-hospital cardiac arrest without ST-segment elevation: A COACT trial substudy. Resuscitation, 2021, 158, 14-22.	1.3	5
197	Outcome and Predictors for Mortality in Patients with Cardiogenic Shock: A Dutch Nationwide Registry-Based Study of 75,407 Patients with Acute Coronary Syndrome Treated by PCI. Journal of Clinical Medicine, 2021, 10, 2047.	1.0	5
198	Ecological momentary assessment versus retrospective assessment for measuring change in health-related quality of life following cardiac intervention. Journal of Patient-Reported Outcomes, 2020, 4, 98.	0.9	5

#	Article	IF	CITATIONS
199	Longâ€term followâ€up after nonurgent percutaneous coronary intervention in unprotected left main coronary arteries. Catheterization and Cardiovascular Interventions, 2010, 75, 1026-1036.	0.7	4
200	Percutaneous left ventricular assist devices for high-risk percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2010, 8, 1247-1255.	0.6	4
201	The first generation ABSORB BVS scaffold; to be or not to be?. Netherlands Heart Journal, 2017, 25, 416-418.	0.3	4
202	Fiveâ€year followâ€up of the endothelial progenitor cell capturing stent versus the paxlitaxelâ€eluting stent in de novo coronary lesions with a high risk of coronary restenosis. Catheterization and Cardiovascular Interventions, 2018, 91, 1212-1218.	0.7	4
203	Cardiology fellows-in-training are exposed to relatively high levels of radiation in the cath lab compared with staff interventional cardiologists—insights from the RECAP trial. Netherlands Heart Journal, 2019, 27, 330-333.	0.3	4
204	Adherence to guideline recommendations for coronary angiography in a poor South-East Asian setting: Impact on short- and medium-term clinical outcomes. Scientific Reports, 2019, 9, 19163.	1.6	4
205	Paclitaxelâ€eluting balloon versus everolimusâ€eluting stent in patients with diabetes mellitus and inâ€stent restenosis: Insights from the randomized DARE trial. Catheterization and Cardiovascular Interventions, 2019, 93, 216-221.	0.7	4
206	Angiographic and clinical outcomes of antegrade versus retrograde techniques for chronic total occlusion revascularizations: Insights from the PRISON IV trial. Catheterization and Cardiovascular Interventions, 2019, 93, E81-E89.	0.7	4
207	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drugâ€eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. Catheterization and Cardiovascular Interventions, 2020, 95, 89-96.	0.7	4
208	A paradox in sex-specific clinical outcomes after bioresorbable scaffold implantation: 2-year results from the AIDA trial. International Journal of Cardiology, 2020, 300, 93-98.	0.8	4
209	Update and, internal and temporal-validation of the FRANCE-2 and ACC-TAVI early-mortality prediction models for Transcatheter aortic Valve Implantation (TAVI) using data from the Netherlands heart registration (NHR). IJC Heart and Vasculature, 2021, 32, 100716.	0.6	4
210	Demonstrating LV unloading on echocardiography during high risk PCI with a left ventricular assist device. Acute Cardiac Care, 2007, 9, 125-126.	0.2	3
211	Clinical outcomes after bareâ€metal stenting in diabetic patients with lesions carrying a low risk of restenosis. Catheterization and Cardiovascular Interventions, 2013, 81, 26-33.	0.7	3
212	Assessment of Cardiac Device Position on Supine Chest Radiograph in the ICU. Critical Care Medicine, 2016, 44, e957-e963.	0.4	3
213	Characteristics and the average 30-day and 6-month clinical outcomes of patients hospitalised with coronary artery disease in a poor South-East Asian setting: the first cohort from Makassar Cardiac Center, Indonesia. BMJ Open, 2018, 8, e021996.	0.8	3
214	Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLOREâ€trial. Catheterization and Cardiovascular Interventions, 2019, 94, 536-545.	0.7	3
215	Brachial Artery Access as a Novel Alternative for Impella 2.5 Insertion. JACC: Case Reports, 2020, 2, 1884-1887.	0.3	3
216	Acute myocardial infarction, chronic total occlusion, and cardiogenic shock: the ultimate triple threat. EuroIntervention, 2018, 14, e252-e254.	1.4	3

#	Article	IF	Citations
217	Percutaneous assist devices vs. intra-aortic balloon pump for cardiogenic shock: evidence under construction vs. expert opinion. European Heart Journal, 2010, 31, 502-502.	1.0	2
218	Continuous postoperative pericardial flushing method versus standard care for wound drainage after adult cardiac surgery: A randomized controlled trial. EBioMedicine, 2020, 55, 102744.	2.7	2
219	Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusion—A subanalysis of the EXPLORE trial. Catheterization and Cardiovascular Interventions, 2021, 97, 1176-1183.	0.7	2
220	Periprocedural Antibiotic Prophylaxis for Transfemoral Transcatheter Aortic Valve Replacement: A Nationwide Survey in the Netherlands. Structural Heart, 2021, 5, 328-329.	0.2	2
221	Admission Lipoprotein-Associated Phospholipase A2 Activity Is Not Associated with Long-Term Clinical Outcomes after ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2014, 9, e96251.	1.1	2
222	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. Interventional Cardiology Review, 2015, 10, 39.	0.7	2
223	Outcomes of bioresorbable vascular scaffolds versus everolimus-eluting stents by coronary complexity: a sub-analysis of the AIDA trial. EuroIntervention, 2020, 16, e904-e912.	1.4	2
224	Ischaemic electrocardiogram patterns and its association with survival in out-of-hospital cardiac arrest patients without ST-segment elevation myocardial infarction: a COACT trials' post-hoc subgroup analysis. European Heart Journal: Acute Cardiovascular Care, 2022, 11, 535-543.	0.4	2
225	Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?. Journal of Thoracic Disease, 2016, 8, E1100-E1102.	0.6	1
226	1-Year Clinical Performance of COMBO Stent Versus XienceÂStent in All-Comers Patients With Coronary ArteryÂDisease. JACC: Cardiovascular Interventions, 2018, 11, 102-103.	1.1	1
227	Patient delay in women with STEMI: Time to raise awareness. International Journal of Cardiology, 2018, 262, 30-31.	0.8	1
228	Reconstructing Disruptive Life Events Using the RE-LIFE Questionnaire: Further Validation of the †Narrative Meaning Making of Life Events†Model Using Multiple Mediation Analysis. Journal of Empirical Theology, 2019, 32, 251-280.	0.6	1
229	Threeâ€year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimusâ€eluting stent in routine PCI in patients with diabetes mellitus— AIDA subâ€study. Catheterization and Cardiovascular Interventions, 2020, 98, 713-720.	0.7	1
230	Continuous postoperative pericardial flushing reduces postoperative bleeding after coronary artery bypass grafting: A randomized trial. EClinicalMedicine, 2021, 31, 100661.	3.2	1
231	Cangrelor Use in Routine Practice: A Two-Center Experience. Journal of Clinical Medicine, 2021, 10, 2829.	1.0	1
232	Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion. International Journal of Cardiovascular Imaging, 2022, 38, 631-641.	0.7	1
233	XIENCE Implantation Followed By Short Dual Antiplatelet Therapy: â€~The New Normal'?. Heart International, 2021, 15, 65.	0.4	1
234	Percutaneous Mechanical Support. Interventional Cardiology Clinics, 2013, 2, ix.	0.2	0

#	Article	IF	CITATIONS
235	Vasoactive and Antiarrhythmic Drugs During Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2013, 2, 665-670.	0.2	O
236	Additional side branch stent placement in patients with long side branch lesions treated with the Tryton dedicated bifurcation side branch stent. International Journal of Cardiology, 2013, 168, 3059-3062.	0.8	0
237	Intracoronary Abciximab in DiabeticÂSTEMIÂPatients. Journal of the American College of Cardiology, 2016, 68, 739-741.	1.2	O
238	Reply. Journal of the American College of Cardiology, 2017, 69, 1758-1759.	1.2	0
239	The first-generation ABSORB BVS: awaiting dissolving outcomes. Netherlands Heart Journal, 2017, 25, 650-652.	0.3	0
240	Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 511-512.	1.1	0
241	Reply. JACC: Cardiovascular Interventions, 2018, 11, 506-507.	1.1	0
242	Recurrent myocardial infarction in an aneurysmal coronary artery managed with stent grafts. Coronary Artery Disease, 2018, 29, 171-173.	0.3	0
243	Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report. Journal of Radiology Case Reports, 2019, 13, 9-14.	0.2	0
244	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. International Journal of Cardiovascular Imaging, 2020, 36, 565-575.	0.7	0
245	Data on sex differences in one-year outcomes of out-of-hospital cardiac arrest patients without ST-segment elevation. Data in Brief, 2020, 33, 106521.	0.5	0
246	Mechanical circulatory support for shock: AÂlittle bit better is just not enough!. Netherlands Heart Journal, 2020, 28, 177-178.	0.3	0
247	Implementation of CT Coronary Angiography as an Alternative to Invasive Coronary Angiography in the Diagnostic Work-Up of Non-Coronary Cardiac Surgery, Cardiomyopathy, Heart Failure and Ventricular Arrhythmias. Journal of Clinical Medicine, 2021, 10, 2374.	1.0	0
248	MGuard Embolic Protection Stent – The Importance of Thrombus Management in ST-elevation Myocardial Infarction Primary Percutaneous Coronary Intervention. Interventional Cardiology Review, 2014, 9, 168.	0.7	0
249	Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. , 2015, , 2281-2296.		0
250	The Impact of a Chronic Total Coronary Occlusion on Outcomes of Patients With an Implantable Cardioverter Defibrillator: Insights From the EXPLORE Trial. Journal of Invasive Cardiology, 2020, 32, E60-E62.	0.4	0
251	The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement. Journal of Invasive Cardiology, 2021, 33, E823-E832.	0.4	0
252	Cost Analysis From a Randomized Comparison of Immediate Versus Delayed Angiography After Cardiac Arrest. Journal of the American Heart Association, 2022, 11, e022238.	1.6	0